

NYMOX PHARMACEUTICAL CORP

Form 6-K

August 07, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

Continuous Disclosure

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

9900 Cavendish Blvd., St. Laurent, QC, Canada, H4M 2V2

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-_____

Nymox Pharmaceutical Corporation

On July 31, 2015 Nymox Pharmaceutical Corporation received formal approvals for its change of domicile to the Bahamas was effective.

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

At the Special Shareholders Meeting of Nymox on April 23, 2015 there was a 94% majority shareholder vote in favor of the Company's change of domicile to the Bahamas. Subsequent to the majority vote in favor, on July 31, 2015 the Company was informed that it has received formal approval from Corporations Canada. The Company's Management are located in Bahamas, the U.S. and Europe. The Company currently maintains offices in the Bahamas, the U.S. and Canada.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
(Registrant)

By: /s/ Paul Averbach
Paul Averbach
President and Chief Executive Officer

Date: August 7, 2015
